CNS Pharmaceuticals Advances Brain Cancer Treatment with Promising TPI 287 Program
August 27, 2025 — CNS Pharmaceuticals advances TPI 287 for brain cancer treatment. CEO discusses glioblastoma progress and clinical trial results in BioMedWire Podcast feature.